Read on Twitter
This thread is going to be a collection of all my #globaloncology papers, primarily for my own reference to bookmark for quick access but also, just in case, it is helpful for any colleague with an interest in global oncology. 1/
This was my first publication ever. A correspondence to @TheLancetOncol in 2014 about cancer care and research in Nepal with @Poudyalbishesh : https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70230-X/fulltext
This is probably one of the most important papers we’ve ever published. This paper in British Journal of Hematology highlights the story of how Bone Marrow Transplant services started in Nepal under @Poudyalbishesh ‘s initiative. https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.13645
This correspondence written with @KAZ99081 tries to explore nuances of the study from India about the futility of surgery in patients with advanced breast cancer. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00368-X/fulltext
I love this paper with @Poudyalbishesh and @DamianoRondell1 . This is a good example of the “jugaad” culture in medicine- frugal innovation of mixing lipids + plain amphotericin when lipsoomal amphotericin is cost-prohibitive. https://www.tandfonline.com/doi/abs/10.3109/10428194.2015.1055485?journalCode=ilal20 cc @BldCancerDoc @barttels2
This is one such article that I actually feel quite proud of having written. My first single author paper but I had the huge opportunity to receive the mentorship of Dr. Len Saltz for this piece. Many thanks to JCO GO @ASCO_pubs for that opportunity. https://ascopubs.org/doi/10.1200/JGO.2015.000588
In this review, we explore the cheaper options available to prevent chemo induced nausea and vomiting for low resource settings. https://ascopubs.org/doi/full/10.1200/jgo.2015.002477 @ASCO_pubs
This was a provocative paper but seeing LMICs spend their limited resources on unproven expensive screening modalities compelled me to write this w/ @KAZ99081 : https://link.springer.com/article/10.1007/s10552-016-0812-8
Another example of jugaad led by @Poudyalbishesh . The title says it all. https://onlinelibrary.wiley.com/doi/abs/10.1111/hae.13017
This one was published in Journal of Nepal Medical Association. Yes, we do have a Pubmed indexed medical journal in Nepal :) http://jnma.com.np/jnma/index.php/jnma/article/view/2832 Again led by @Poudyalbishesh
This one was a letter to the FDA about the need to individualize the dose of drugs based on ethnic differences. Speaking on behalf of Japanese patients here :) https://clincancerres.aacrjournals.org/content/23/19/5993
This piece explores the issues surrounding the inaffordability of avastin for advanced cervical cancer in LMICs like Nepal. https://ascopubs.org/doi/full/10.1200/JGO.2016.004895
This is another paper that I’m particularly proud of. We explore the economic issues with new cancer drugs here. My first opportunity to work with the inspirational mentor @SullivanProf https://www.tandfonline.com/doi/full/10.1080/20502877.2017.1314885
Yes, cancer drugs are cheaper in LMICs. But that doesn’t mean that they’re affordable. https://www.oncotarget.com/article/21976/pdf/
This paper in @ecancer was when I first came up with the concept of “Avoiding Wisely”. Avoiding low-value oncology interventions is important for all countries but more so for LMICs. https://ecancer.org/en/journal/article/727-low-value-practices-in-oncology-contributing-to-financial-toxicity
And this paper in @ecancer with colleagues from @Anticancerfund cautions the oncology world re rejection bias against drug repurposing. https://ecancer.org/en/journal/editorial/76-does-the-oncology-community-have-a-rejection-bias-when-it-comes-to-repurposed-drugs @Simple_Trials @AnticancerOrgUK
